Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023
26 Julho 2023 - 8:00AM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
injuries, today announced that it will report second quarter 2023
financial results on Monday, August 7, 2023 after the market
closes. Axogen management will host an investment-community
conference call and webcast at 4:30 p.m. ET following the release.
Investors interested in participating in the conference call by
phone may do so by dialing toll free at (877) 407-0993 or use the
direct dial-in number at (201) 689-8795. Those interested in
listening to the conference call live via the Internet may do so by
visiting the Investors page of the company's website at
www.axogeninc.com and clicking on the webcast link.
Following the conference call, a replay will be available in the
Investors section of the company's website at
www.axogeninc.com.
About AxogenAxogen (AXGN) is the leading
Company focused specifically on the science, development, and
commercialization of technologies for peripheral nerve regeneration
and repair. Axogen employees are passionate about helping to
restore peripheral nerve function and quality of life to patients
with physical damage or transection to peripheral nerves by
providing innovative, clinically proven, and economically effective
repair solutions for surgeons and health care providers. Peripheral
nerves provide the pathways for both motor and sensory signals
throughout the body. Every day, people suffer traumatic injuries or
undergo surgical procedures that impact the function of their
peripheral nerves. Physical damage to a peripheral nerve, or the
inability to properly reconnect peripheral nerves, can result in
the loss of muscle or organ function, the loss of sensory feeling,
or the initiation of pain.
Axogen's platform for peripheral nerve repair features a
comprehensive portfolio of products, including Avance® Nerve Graft,
a biologically active off-the-shelf processed human nerve allograft
for bridging severed peripheral nerves without the comorbidities
associated with a second surgical site; Axoguard Nerve Connector®,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard Nerve
Protector®, a porcine submucosa ECM product used to wrap and
protect damaged peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments; Axoguard
HA+ Nerve Protector™, a porcine submucosa ECM base layer coated
with a proprietary hyaluronate-alginate gel, is a next-generation
technology designed to provide short- and long-term protection for
peripheral nerve injuries; and Axoguard Nerve Cap®, a porcine
submucosa ECM product used to protect a peripheral nerve end and
separate the nerve from the surrounding environment to reduce the
development of symptomatic or painful neuroma. The Axogen portfolio
of products is available in the United States, Canada, Germany, the
United Kingdom, Spain, South Korea, and several other
countries.
Contact:Axogen,
Inc.InvestorRelations@axogeninc.com
Axogen (NASDAQ:AXGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Axogen (NASDAQ:AXGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024